Skip to main content
OpenTrials
Completed

NCT Number: NCT00687492

Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Hong Kong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 2 or more risk factors (according to NCEP ATP III guideline)
  • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion criteria

  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in a clinical study during the last 90 days.

Treatment and study plan

Primary outcomes

  1. The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country)

    Time frame: After collecting all Patient Record Form.

Secondary outcomes

  1. The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets.

    Time frame: After collecting all Patient Record Form.

  2. The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables.

    Time frame: After collecting all Patient Record Form.

  3. The physician characteristics associated with the allocation of hypercholesterolemia treatment regime.

    Time frame: After collecting all Patient Record Form.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: CEPHEUS

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
May 30, 2008
Registry last updated
Dec 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.